Living Donor Navigation for Kidney Disease
(PILOT Trial)
Trial Summary
What is the purpose of this trial?
We hypothesize that expansion of the Living Donor Navigator (LDN) program to include tele-health delivery will overcome geographic disparities in access and facilitate sustained increases in living donation. We will utilize an individually randomized group trial (IRGT) design with delayed intervention initiation to compare the effectiveness of tele-health LDN model to standard of care.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the Living Donor Navigator Program treatment for kidney disease?
Is the Living Donor Navigation for Kidney Disease program safe for participants?
How is the Living Donor Navigator Program treatment different from other treatments for kidney disease?
The Living Donor Navigator Program is unique because it pairs kidney transplant candidates with a friend or family member who acts as an advocate, helping to identify potential donors and navigate the healthcare system. This program focuses on enhancing advocacy and providing support tools for both candidates and their caregivers, which is not typically addressed in standard treatments for kidney disease.12789
Research Team
Vineeta Kumar, MD
Principal Investigator
University of Alabama at Birmingham
Eligibility Criteria
This trial is for adults over 18 with end-stage kidney disease who are evaluating their options for a kidney transplant. It's open to English speakers, including deaf individuals with interpreters. People unwilling to consider living donors or those under 18 cannot participate.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the Living Donor Navigator (LDN) program, consisting of four educational sessions over two months, either in-person or via tele-health.
Follow-up
Participants are monitored for the number of live donor screenings and approvals within 3 months.
Treatment Details
Interventions
- Living Donor Navigator Program
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator